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Abstract
Background: The purpose of this study was to evaluate the effect of apple cider vinegar plus 
PPI-based triple therapy on eradication of Helicobacter Pylori (H.pylori) infection. Materials 
and Methods: 116 patients with H. pylori infection were included in this randomized clinical 
trial. Patients in control group (n=59) received amoxicillin, clarithromycin, and pantaprazole 
twice daily. Patients in study group (57 patients) received the same regimen plus 30 mL of apple 
cider vinegar twice daily. The duration of therapy for study and control were 10 and 14 days 
respectively. Four weeks after the completion of therapy, Urea breath test was performed to 
assess the success of H.pylori infection eradication. Results: 86% of patients in control group 
in comparison to 88% in apple cider vinegar group responded to eradication therapy (P=0.41). 
Conclusion: Addition of apple cider vinegar to proton pomp inhibitor (PPI)-based triple thera-
py may decrease the duration of H. pylori treatment but it was not statistically significant. Thus, 
our results showed no efficacy of apple cider vinegar in H. pylory eradication treatment.[GMJ. 
2014;3(2):90-94]
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Introduction
Helicobacter pylori (H. pylori) is a mi-cro-aerophilic Gram-negative, spi-
ral-shaped, motile bacterium that colonizes 
the gastric mucosa of humans and is estimated 
to inhabit in at least half of the world’s human 
population [1].
Multiple regimens have been evaluated for H. 
pylori therapy in randomized controlled trials 
[2-6]. Despite the number of studies, the op-
timal therapeutic regimen has not yet beende-
fined.
The regimen most commonly recommended 
for first line treatment of H. pylori is triple 
therapy with a proton pump inhibitor, amox-
icillin, and clarithromycin for 14 days. How-
ever, themulti-drug application is associated 
with remarkable side effects and sometimes 
patients do not complete the treatment course. 
Thus, treatment failure is associated with H. 
pylori strains that are resistant to the common-
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ly used antibiotics [7]. Crude extracts and iso-
lated compounds from plants used in herbal 
traditional medicines have been tested for an-
ti-H. pylori activity in vitro, in animal models, 
as well as in clinical studies as possible sourc-
es for alternative eradication therapies [8-10]. 
One study showed the in vitro anti-H.pylori 
activity of some carotenoids of the apple peel 
extracts [11]. Apple cider vinegar (ACV), 
which is derived from apple, contains 4% ace-
tic acid, polyphenols, pectin and carotenoids 
with antibacterial and prebiotic properties 
[12-14]. As ACV have antimicrobial activity 
and to our knowledge, there has been no study 
to assay the anti H. pylori activity of ACV; 
therefore, we conducted a prospective con-
trolled study with the aim of testing whether 
adding ACV supplement to a ten-day proton 
pump inhibitor based (PPI-based) triple ther-
apy could have an acceptable influence on H. 
pylori eradication in comparison with the rou-
tine two week anti-H. pylori regimen.
Materials and Methods
One hundred twenty patients with an indica-
tion for endoscopy of dyspeptic symptoms 
who were admitted to a gastroenterological 
clinic of Emam Ali university hospital in Ilam 
from March 2011 to September 2012 were in-
cluded in this randomized clinical trial study. 
Patients were matched for sex and random-
ly divided into two groups. All patients un-
derwent endoscopy and Rapid Urease Test 
(RUT). RUT positive patients without ulcer 
were selected for the study. Exclusion criteria 
were consumption of H2 antagonists, proton 
pump inhibitors and antibiotics in four recent 
weeks. Also, the ones who had gastrointes-
tinal bleeding in recent four weeks were ex-
cluded from the study. The study protocol was 
approved by responsible ethics committee and 
registered in Iranian registry of clinical trials 
with code of IRCT2013100614901N1. Fur-
thermore, informed consents were obtained 
from the participants. Patients were ran-
domised by using a computer-generated list to 
receive either a standard 14-day triple therapy 
with 40 mg pantaprazol, 1 g amoxicillin, and 
500 mg clarithromycin twice daily in control 
group or the same drug regimen plus 30 mL of 
raw, unfiltered ACV in a glass of water twice 
daily after meal for 10 days in study group. 
Red delicious apples were used to produce 
natural apple cider in laboratory of nutrition 
department. The duration of the therapy for 
the study group was ten days (for receiving 
ACV). The patients were asked to return to 
assess the compliance with the therapy, and 
to estimate the incidence of side effects at the 
end of the treatment. The compliance was de-
fined as the consumption of >90% of the pre-
scribed drugs and ACV by personal interview 
at the follow-up visit at the end of the thera-
py. During the four consecutive weeks after 
discontinuation of the treatment, the patients 
were free of medication. After this period, 
urea breath test (UBT) was performed for all 
the participants.
SPSS software 14.0 was used for data analy-
sis. Student t test was used to compare con-
tinuous variables in two groups. Categorical 
data between the groups were compared using 
the Chi-square test. P-value less than 0.05 was 
considered as significant.
Results
The mean age of patients was 42.5±3.5 years. 
One patient in the study group and three pa-
tients in control group stopped the treatment 
due to non-compliance and minor side effects. 
These side effects in control group were vom-
iting, loose stool, and headache in the study 
group. Therefore a total of 59 patients in ACV 
group and 57 patients in control group com-
pleted the study. The duration of therapy in 
study group was 10 days versus two weeks 
in control group. Endoscopic results in study 
group were as 4 patients with ulcer, 20 erythe-
ma, 17 erosion and 18 without obvious lesion. 
These findings in control group were as 4 pa-
tients with ulcer, 19 erythema, 18 erosion and 
16 without obvious lesion.
The eradication rate of H. pylori was 88% in 
study group and 86% in control group (P= 
0.41) (Table-1). The H. pylori eradication rate 
did not differ between male and female pa-
tients (48/55, 87% vs. 53/61, 86%; p = 0.71). 
Also eradication rate did not differ between 
smokers and non-smokers (17/20, 85% vs. 
84/96, 87%; P = 0.81).





In our study we assumed that adding ACV to 
PPI-based triple therapy might reduce the
duration of the antibacterial treatment for the 
eradication of H. pylori infection, though it 
was not considerable according to statistical 
analyses. Unfortunately, there are two prob-
lems with H. pylori treatment; resistance to 
antibiotics that are commonly used in a num-
ber of eradication regimens and compliance 
with medications. It has been shown that Met-
ronidazole resistance is significantly more 
common in women and Clarithromycin resis-
tance is significantly associated with the geo-
graphic region, older age,and the presence of 
inactive ulcer disease [15]. The side effects of 
the medications are reported in up to 50 per-
cent of patients taking the triple therapy reg-
imens [16]. As the duration of anti H. pylori 
therapy is long, the compliance of the patients 
is weak and they discontinue their treatment. 
Thus, the treatment failure is associated with 
the H. pylori strains which are resistant to the 
commonly used antibiotics. Since an initial at-
tempt at eradicating H. pylori fails in approxi-
mately 20 percent of the patients [17], contin-
uous search for novel therapeutic approaches 
to cure H. pylori is needed. Some new, botan-
ical therapy regimens have been recently pro-
posed [8-11]. Raw, unfiltered ACV is an anti-
bacterial agent and a good source of prebiot-
ics. The anti-bacterial effect of ACV is known 
against different pathogens in vitro [12-13]. 
It has shown that apple has in vitro anti-H.
pylori activity comparable to metronidazole 
[11]. ACV is also a good source of prebiotics. 
In the large intestine and colon, microorgan-
isms degrade pectin and liberate oligofructose 
and short-chain fatty acids that have prebiotic 
effects [14]. Prebiotics stimulate the growth 
and/or the activity of bifidobacteria and lac-
tic acid bacteria in the digestive system. It has 
been shown that probiotics, which are live 
nonpathogenic bifidobacteria and lactic acid 
bacteria that benefit a host through altering 
gut microflora composition, may reduce the 
side effects of standard H. pylori treatments, 
especially diarrhea. As a result, they may be 
useful adjuncts to improve the tolerability and 
compliance with more traditional antibiotic 
regimens [18-19]. As some probiotics have 
antimicrobial effects [20, 21], they have been 
proposed as treatment for H. pylori infection 
but they should not be considered a substitute 
for standard antibiotic treatments [22].
ACV also has galacturonic acid which reduces 
the gastrointestinal tract inflammation in the
animal model [23]; thus may reduce the side 
effects of standard H. pylori treatments.
ACV has significant amount of phenolics [24]. 
As free radicals play an important role in the 
pathogenesis of gastroduodenal mucosal in-
flammation, peptic ulcer disease and probably 
even gastric cancer, various micronutrients 
with antioxidant compouds are considered to 
protect the gastric mucosa by scavenging the 
free radicals [25].
On the other hand proton pump inhibitor 
agents which are used in PPI-based triple ther-
apy act by selectively oxidizing thiol targets in 
the gastric proton pump, but they also appear 
to be toxic to the gastric mucosa. It has been 
shown that antioxidant therapy prevents this 
toxic effect [26]. Thus the presence of signif-
icant amount of phenolics in ACV may have 
preventive effects on the oxidative damage of 
PPI agents [27].
Conclusions
Addition of raw, unfiltered ACV to H. pylori 
treatment regimen of amoxicillin, clarithro-
mycin and pantaprazole may decrease dura-













Smoking 11 9 0.8
Eradication 
Rate 52.59  49.57 0.4
Days of 
Therapy 14 10 0.04
Analysis by independent t test
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tion of H. pylori treatment, better compliance 
in patients and therefore might decrease bac-
terial resistance to antibiotics.,Although our 
results showed no significant difference in 
H. pylory eradication by adding ACV to the 
regimen, but the same results was seen in the 
ACV group by a 10 days trial compared to the 
control group by a two weeks treatment. Giv-
en the small sample size in this trial, larger 
studies are needed to confirm these benefits. 
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